Research advance in Clostridium difficile vaccine

Abstract

The risk factors of Clostridium difficile infections increased in recent years, such as the underlying disease, hospitalization duration, age, the use of antibiotics, the use of proton pump inhibitors and so on. The rate of Clostridium difficile infection and recurrence are still high despite the appear of new antibiotics such as rifaximin, nitazoxanide, tigecycline, ramoplanin, fidaxomicin, and non-antimicrobial such as drugs toxin neutralizer chamber, biological therapeutic agents, fecal transplantation, systemic antibody method, intravenous immunoglobulin and so on. The vaccine is the most ideal way of prevention and treatment of Clostridium difficile infection. The research in Clostridium difficile vaccine lasted for nearly 20 years. Except the monoclonal antibody vaccine and toxoid vaccine against toxin A and toxin B have achieved better results in the human, some recombinant vaccines against the toxin receptor and the key pathogenic factor of Clostridium difficile also achieved good effect in animal.（Chin J Lab Med,2014,37:430-433） Key words: Clostridium difficile; Vaccines, synthetic; Toxoids